Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients

Abstract

Systemic exposure to capecitabine and its metabolites in plasma is poorly predictive of safety and efficacy. The present results have no clinical implications for the use of capecitabine and argue against the value of therapeutic drug monitoring for dosage adjustment.